TargTex is determined to find novel correlations between small molecules and targets that are overexpressed in oncological indication. Our lead product is being developed as an adjunct to surgery taking advantage its selectivity towards an unexplored target in Glioblastoma.

TargTex is developing a concerted approach: aligning scientists, physicians and patients to advance innovative therapies against daunting diseases with few treatment options. We have built collaborations with top-tier institutions worldwide to achieve this goal.

We aim to give Glioblastoma patients a chance to live instead of merely surviving.